Daily Sundial

Best Alternative to Linzess for IBS and Constipation – Cheaper and Natural Linzess Alternatives Over the Counter

Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by increasing fluid in the intestines and ...
Monthly Prescribing Reference

Linzess Approved for Pediatric Functional Constipation

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...
Healio

FDA approves Linzess as first treatment for pediatric functional constipation

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
Becker's ASC

FDA Approves Linzess for Irritable Bowel Syndrome and Constipation

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...
Healio

AbbVie submits sNDA for functional constipation treatment in pediatric patients

Please provide your email address to receive an email when new articles are posted on . AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of ...
Business Wire

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...
Seeking Alpha

AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to ...

If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data ...
Business Wire

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric ...